ImmunityBio (NASDAQ:IBRX) Shares Down 9.8% – Here’s What Happened

ImmunityBio, Inc. (NASDAQ:IBRX) shares traded down 9.8% during mid-day trading on Monday . The company traded as low as $6.57 and last traded at $6.66. 24,132,524 shares were traded during mid-day trading, a decline of 39% from the average session volume of 39,348,066 shares. The stock had previously closed at $7.38.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio secured $100 million of financing (including $75 million of non‑dilutive royalty financing) to support global expansion and pipeline advancement — improves near‑term liquidity and reduces immediate dilution risk. ImmunityBio Strengthens Balance Sheet with $100 Million of Financing
• Positive Sentiment: High‑profile media commentary has been supportive: Jim Cramer publicly suggested investors may consider owning IBRX as a speculative position, which can attract retail interest and short‑term buying. Jim Cramer on ImmunityBio
• Neutral Sentiment: Analysts and market writeups note recent volatility and strong quarterly performance metrics, prompting debate on whether the stock merits reassessment after rapid swings. These pieces provide context but are less likely to move price than regulatory/legal headlines. ImmunityBio Rallies as Firm Raises $100M
• Negative Sentiment: The FDA sent a warning letter saying promotional claims about ImmunityBio’s lead biologic (Anktiva) were misleading; that finding sparked a sharp earlier selloff and is the core catalyst for today’s decline as investors reassess regulatory and commercialization risk. ImmunityBio Receives FDA Warning Letter
• Negative Sentiment: Multiple securities‑fraud class actions and investor‑notification filings have been announced (several law firms seeking lead plaintiffs, deadlines in late May), increasing potential legal exposure, uncertainty over damages, and ongoing headline risk that is pressuring the stock. ImmunityBio Sued After FDA Flags Misleading Cancer Claims

Analyst Ratings Changes

IBRX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. D. Boral Capital restated a “buy” rating and set a $23.00 price target on shares of ImmunityBio in a report on Monday, March 23rd. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. Jefferies Financial Group upped their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, BTIG Research started coverage on ImmunityBio in a research report on Thursday, March 12th. They issued a “buy” rating and a $13.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.40.

ImmunityBio Stock Down 6.9%

The business has a 50-day simple moving average of $7.72 and a 200-day simple moving average of $4.31. The company has a market cap of $7.34 billion, a PE ratio of -18.79 and a beta of -0.03.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. As a group, equities research analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

Insider Activity

In other news, Director Barry J. Simon sold 165,000 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares of the company’s stock, valued at approximately $29,989,665.25. This trade represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christobel Selecky sold 50,000 shares of ImmunityBio stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 501,967 shares of company stock valued at $4,466,412. 69.48% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors have recently modified their holdings of IBRX. Vanguard Group Inc. increased its position in shares of ImmunityBio by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after acquiring an additional 5,122,052 shares during the period. State Street Corp grew its stake in ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company’s stock worth $32,582,000 after purchasing an additional 5,139,890 shares in the last quarter. Geode Capital Management LLC grew its stake in ImmunityBio by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock worth $15,684,000 after purchasing an additional 1,030,113 shares in the last quarter. Armistice Capital LLC purchased a new stake in ImmunityBio during the 2nd quarter worth about $20,497,000. Finally, Heights Capital Management Inc. purchased a new stake in ImmunityBio during the 3rd quarter worth about $16,152,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.